Back to resultsGlioblastoma and Individualized Therapies
Primary Purpose
Glioma, Malignant
Status
Available
Phase
Locations
Germany
Study Type
Expanded Access
Intervention
Vaccination
Sponsored by
About this trial
This is an expanded access trial for Glioma, Malignant
Eligibility Criteria
Inclusion Criteria:
- malignant glioma, IDH WT
Exclusion Criteria:
- na
Sites / Locations
- Zentrum für Humangenetik Tübingen
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT05356312
First Posted
April 11, 2022
Last Updated
April 27, 2022
Sponsor
Zentrum fur Humangenetik Tuebingen
1. Study Identification
Unique Protocol Identification Number
NCT05356312
Brief Title
Glioblastoma and Individualized Therapies
Official Title
Retrospective Analysis of Glioblastoma Patients With Immune Therapies
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zentrum fur Humangenetik Tuebingen
4. Oversight
5. Study Description
Brief Summary
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioma, Malignant
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
Vaccination
Intervention Description
Personalized neoantigen vaccination
10. Eligibility
Sex
All
Eligibility Criteria
Inclusion Criteria:
malignant glioma, IDH WT
Exclusion Criteria:
na
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Saskia Biskup, Dr. Dr.
Phone
+49 (0)7071 565 44 00
Email
Saskia.Biskup@humangenetik-tuebingen.de
Facility Information:
Facility Name
Zentrum für Humangenetik Tübingen
City
Tübingen
Country
Germany
Individual Site Status
Available
12. IPD Sharing Statement
Learn more about this trial
Glioblastoma and Individualized Therapies
We'll reach out to this number within 24 hrs